Clinical Trials Directory

Trials / Completed

CompletedNCT02792647

A Study of Multiple Oral Doses of IX-01 in Healthy Male Subjects

A Double-blind, Randomised, Placebo-controlled, Parallel Group, Dose Escalation Study to Investigate the Safety, Toleration, and Pharmacokinetics of Multiple Oral Doses of IX-01 in Healthy Male Subjects

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
24 (actual)
Sponsor
Ixchelsis Limited · Industry
Sex
Male
Age
18 Years – 45 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to investigate the safety and tolerability of IX-01 after multiple doses, and to determine the PK of IX-01 and activity of CYP3A4.

Conditions

Interventions

TypeNameDescription
DRUGPlaceboAdministered orally
DRUGIX-01Administered orally

Timeline

Start date
2016-05-01
Primary completion
2016-07-01
Completion
2016-10-01
First posted
2016-06-07
Last updated
2016-11-10

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT02792647. Inclusion in this directory is not an endorsement.